Actions of rilmenidine on neurogenic hypertension in BPH/2J genetically hypertensive mice

Kristy L Jackson, Kesia Palma-Rigo, Thu-Phuc Nguyen-Huu, Geoffrey A Head

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)


OBJECTIVE: BPH/2J hypertensive mice have an exaggerated sympathetic contribution to blood pressure (BP). Premotor sympathetic neurons within the rostroventrolateral medulla (RVLM) are a major source of sympathetic vasomotor tone and major site of action of the centrally acting sympatholytic agent, rilmenidine. The relative cardiovascular effect of rilmenidine in BPH/2J versus normotensive BPN/3J mice was used as an indicator of the involvement of the RVLM in the sympathetic contribution to hypertension in BPH/2J mice. METHODS: BPH/2J and BPN/3J mice were pre-implanted with telemetry devices to measure BP in conscious unrestrained mice. Rilmenidine was administered acutely (n=7-9/group), orally for 14 days, at a wide range of doses (n=5/group), and also infused intracerebroventricularly for 7 days (n=6/group). RESULTS: Acute intraperitoneal rilmenidine induced greater depressor and bradycardic responses in BPH/2J than BPN/3J mice (Pstrain0.16). CONCLUSION: The sympathetic vasomotor inhibitory effect of rilmenidine is minimal in both strains and similar in hypertensive BPH/2J and BPN/3J mice. Thus, hypertension in BPH/2J mice is not likely mediated by greater neuronal activity in the RVLM, and agents such as rilmenidine would be an ineffective treatment for this form of neurogenic hypertension.
Original languageEnglish
Pages (from-to)575 - 586
Number of pages12
JournalJournal of Hypertension
Issue number3
Publication statusPublished - 2014

Cite this